natgillin/translations-raw huggingface dataset:
Only limited experience with overdose is available from clinical studies and post-marketing experience.
Iz kliničkih ispitivanja i nakon stavljanja lijeka u promet dostupno je samo ograničeno iskustvo u vezi s predoziranjem.
Very rare
Vrlo rijetko napadaji
In another monotherapy study in mild to moderate Alzheimer's disease a total of 470 patients (MMSE total scores at baseline of 11 - 23) were randomised.
U drugom monoterapijskom ispitivanju blage do umjerene Alzheimerove bolesti randomizirano je ukupno 470 bolesnika (početne vrijednosti ukupnog MMSE od 11-23).
Psychotic reactions
Nepoznato psihotične reakcije
Marixino 10 mg film-coated tablets Each film-coated tablet contains 51.45 mg lactose monohydrate.
Marixino 10 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 51,45 mg laktoze hidrata.
Each film-coated tablet contains 10 mg memantine hydrochloride equivalent to 8.31 mg memantine.
Svaka filmom obložena tableta sadrži 10 mg memantinklorida, što odgovara 8,31 mg memantina.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Unutar pojedine skupine učestalosti nuspojave su prikazane u padajućem nizu prema ozbiljnosti.
• Periodic Safety Update Reports
• Periodička izvješća o neškodljivosti lijeka
The usual starting dose is half a tablet once a day (1 x 5 mg) for the first week.
Uobičajena početna doza iznosi pola tablete jedanput na dan (1 x 5 mg) tijekom prvog tjedna.
A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
Pivotalno ispitivanje monoterapije u populaciji bolesnika koji pate od umjerene do teške Alzheimerove bolesti (početne vrijednosti kratkog testa određivanja mentalnog statusa (MMSE) bile su 3-14) uključivalo je ukupno 252 ambulantna bolesnika.
Marixino 20 mg film-coated tablets Each film-coated tablet contains 102.90 mg lactose monohydrate.
Marixino 20 mg filmom obložene tablete Svaka filmom obložena tableta sadrži 102,90 mg laktoze hidrata.
The following Adverse Reactions listed in the table below have been accumulated in clinical studies with memantine and since its introduction in the market.
Sljedeće nuspojave koje su prikupljene tijekom kliničkih ispitivanja s memantinom i nakon stavljanja lijeka u promet su prikazane u tablici ispod.
Memantine is a voltage-dependent, moderate-affinity uncompetitive NMDA-receptor antagonist.
Memantin je nekompetitivni antagonist NMDA-receptora, umjerenog afiniteta i ovisan o naponu.
Marixino contains the active substance memantine hydrochloride.
Marixino sadrži djelatnu tvar memantinklorid.
Administration of Marixino is not recommended in patients with severe hepatic impairment.
Ne preporučuje se primjena lijeka Marixino kod bolesnika s teškim oštećenjem jetre.
Each film-coated tablet contains 20 mg memantine hydrochloride equivalent to 16.62 mg memantine.
Svaka filmom obložena tableta sadržava 20 mg memantinklorida što odgovara 16,62 mg memantina.
Week 3 (day 15-21) The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
3. tjedan (15-21. dan) Bolesnik treba uzimati jednu i pol filmom obloženu tabletu od 10 mg (15 mg) dnevno tijekom 7 dana.
Tablet core: lactose monohydrate, microcrystalline cellulose (E460), anhydrous colloidal silica, talc (E553b), magnesium stearate (E470b).
Jezgra tablete: laktoza hidrat, mikrokristalična celuloza (E460), koloidni bezvodni silicijev dioksid, talk (E553b), magnezijev stearat (E470b).
Film coating: methacrylic acid-ethyl acrylate copolymer (1:1), sodium laurilsulfate, polysorbate 80, talc (E553b), triacetin, simeticone.
Film ovojnica: metakrilatna kiselina/etilakrilat kopolimer (1:1), natrijev laurilsulfat, polisorbat 80, talk (E553b), triacetin, simetikon.
Week 2 (day 8-14) The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
2. tjedan (8-14. dan) Bolesnik treba uzimati jednu filmom obloženu tabletu od 10 mg (10 mg) dnevno tijekom 7 dana.
Uncommon (may affect up to 1 in 100 people): - Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism).
Manje česte (mogu se javiti u manje od 1 na 100 osoba): - Umor, gljivične infekcije, smetenost, halucinacije, povraćanje, poremećaj hoda, zatajenje srca i zgrušavanje venske krvi (tromboza/tromboembolija).
Week 1 (day 1-7) The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
1. tjedan (1-7. dan) Bolesnik treba uzimati polovicu filmom obložene tablete od 10 mg (5 mg) dnevno tijekom 7 dana.
In post-marketing experience these reactions have been reported in patients treated with memantine.
Ove su nuspojave prijavljene nakon stavljanja lijeka u promet kod bolesnika liječenih memantinom.
- There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is co-administered with HCT or any combination with HCT.
- Pri istodobnoj primjeni memantina i hidroklorotiazida (HCT-a) ili bilo koje od kombinacija s HCT-om, postoji mogućnost smanjenja koncentracije HCT-a u serumu.
Two 10 mg tablets
Dvije tablete od 10 mg
One and a half 10 mg tablets
Jedna i pol tableta od 10 mg
Gait abnormal
Manje često abnormalni hod
White, oval, biconvex film-coated tablet, scored on one side (tablet length: 12.2-12.9 mm, thickness: 3.5-4.5 mm).
Bijela, ovalna, bikonveksna filmom obložena tableta, s razdjelnom crtom na jednoj strani (dužina tablete: 12,2-12,9 mm, debljina: 3,5-4,5 mm).
One 10 mg tablet
Jedna tableta od 10 mg
Lactose monohydrate Cellulose, microcrystalline (E460) Silica, colloidal anhydrous Talc (E553b)
Jezgra tablete laktoza hidrat celuloza, mikrokristalična (E460) silicijev dioksid, koloidni, bezvodni talk (E553b) magnezijev stearat (E470b)
Marixino 10 mg film-coated tablets Marixino 20 mg film-coated tablets
Marixino 10 mg filmom obložene tablete Marixino 20 mg filmom obložene tablete
Common (may affect up to 1 in 10 people): - Headache, sleepiness, constipation, elevated liver function test, dizziness, balance disorders,
Česte (mogu se javiti u manje od 1 na 10 osoba): - Glavobolja, pospanost, zatvor, povišeni rezultati testova jetrene funkcije, omaglica, poremećaji ravnoteže, nedostatak zraka, visoki krvni tlak i preosjetljivost na lijek.
Film coating: methacrylic acid-ethyl acrylate copolymer (1:1),sodium laurilsulfate, polysorbate 80, talc (E553b), triacetin, simeticone.
Film ovojnica metakrilatna kiselina/etilakrilat kopolimer (1:1) natrijev laurilsulfat polisorbat 80 talk (E553b) triacetin simetikon
Marixino 10 mg film-coated tablets
Marixino 10 mg filmom obložene tablete
Marixino 20 mg film-coated tablets
Marixino 20 mg filmom obložene tablete
What Marixino looks like and contents of the pack White, oval, biconvex film-coated tablets, scored on one side (tablet length: 12.2-12.9 mm, thickness: 3.5-4.5 mm).
Bijele, ovalne, bikonveksne filmom obložene tablete s razdjelnom crtom na jednoj strani (dužina tablete: 12,2-12,9 mm, debljina: 3,5-4,5 mm).
Marixino 20 mg film-coated tablets memantine hydrochloride
Marixino 20 mg filmom obložene tablete memantinklorid
Marixino 10 mg film-coated tablets memantine hydrochloride
Marixino 10 mg filmom obložene tablete memantinklorid
White, oval, biconvex film-coated tablet (tablet length: 15.7-16.4 mm, thickness: 4.7-5.7 mm).
Bijela, ovalna, bikonveksna filmom obložena tableta (dužina tablete: 15,7-16,4 mm, debljina: 4,7-5,7 mm).
Half a 10 mg tablet
Pola tablete od 10 mg
14 film-coated tablets: EU/1/13/820/001 28 film-coated tablets: EU/1/13/820/002 30 film-coated tablets: EU/1/13/820/003 42 film-coated tablets: EU/1/13/820/004 50 film-coated tablets: EU/1/13/820/005 56 film-coated tablets: EU/1/13/820/006 60 film-coated tablets: EU/1/13/820/007 70 film-coated tablets: EU/1/13/820/008 84 film-coated tablets: EU/1/13/820/009 90 film-coated tablets: EU/1/13/820/010 98 film-coated tablets: EU/1/13/820/011 100 film-coated tablets: EU/1/13/820/012 112 film-coated tablets: EU/1/13/820/013
14 filmom obloženih tableta: EU/1/13/820/001 28 filmom obloženih tableta: EU/1/13/820/002 30 filmom obloženih tableta: EU/1/13/820/003 42 filmom obložene tablete: EU/1/13/820/004 50 filmom obloženih tableta: EU/1/13/820/005 56 filmom obloženih tableta: EU/1/13/820/006 60 filmom obloženih tableta: EU/1/13/820/007 70 filmom obloženih tableta: EU/1/13/820/008 84 filmom obložene tablete: EU/1/13/820/009 90 filmom obloženih tableta: EU/1/13/820/010 98 filmom obloženih tableta: EU/1/13/820/011 100 filmom obloženih tableta: EU/1/13/820/012 112 filmom obloženih tableta: EU/1/13/820/013
14 film-coated tablets: EU/1/13/820/014 28 film-coated tablets: EU/1/13/820/015 30 film-coated tablets: EU/1/13/820/016 42 film-coated tablets: EU/1/13/820/017 50 film-coated tablets: EU/1/13/820/018 56 film-coated tablets: EU/1/13/820/019 60 film-coated tablets: EU/1/13/820/020 70 film-coated tablets: EU/1/13/820/021 84 film-coated tablets: EU/1/13/820/022 90 film-coated tablets: EU/1/13/820/023 98 film-coated tablets: EU/1/13/820/024 100 film-coated tablets: EU/1/13/820/025 112 film-coated tablets: EU/1/13/820/026
14 filmom obloženih tableta: EU/1/13/820/014 28 filmom obloženih tableta: EU/1/13/820/015 30 filmom obloženih tableta: EU/1/13/820/016 42 filmom obložene tablete: EU/1/13/820/017 50 filmom obloženih tableta: EU/1/13/820/018 56 filmom obloženih tableta: EU/1/13/820/019 60 filmom obloženih tableta: EU/1/13/820/020 70 filmom obloženih tableta: EU/1/13/820/021 84 filmom obložene tablete: EU/1/13/820/022 90 filmom obloženih tableta: EU/1/13/820/023 98 filmom obloženih tableta: EU/1/13/820/024 100 filmom obloženih tableta: EU/1/13/820/025 112 filmom obloženih tableta: EU/1/13/820/026
EU/1/13/820/014 14 film-coated tablets EU/1/13/820/015 28 film-coated tablets EU/1/13/820/016 30 film-coated tablets EU/1/13/820/017 42 film-coated tablets EU/1/13/820/018 50 film-coated tablets EU/1/13/820/019 56 film-coated tablets EU/1/13/820/020 60 film-coated tablets EU/1/13/820/021 70 film-coated tablets EU/1/13/820/022 84 film-coated tablets EU/1/13/820/023 90 film-coated tablets EU/1/13/820/024 98 film-coated tablets EU/1/13/820/025 100 film-coated tablets EU/1/13/820/026 112 film-coated tablets
EU/1/13/820/014: 14 filmom obloženih tableta EU/1/13/820/015: 28 filmom obloženih tableta EU/1/13/820/016: 30 filmom obloženih tableta EU/1/13/820/017: 42 filmom obložene tablete EU/1/13/820/018: 50 filmom obloženih tableta EU/1/13/820/019: 56 filmom obloženih tableta EU/1/13/820/020: 60 filmom obloženih tableta EU/1/13/820/021: 70 filmom obloženih tableta EU/1/13/820/022: 84 filmom obložene tablete EU/1/13/820/023: 90 filmom obloženih tableta EU/1/13/820/024: 98 filmom obloženih tableta EU/1/13/820/025: 100 filmom obloženih tableta EU/1/13/820/026: 112 filmom obloženih tableta
EU/1/13/820/001 14 film-coated tablets EU/1/13/820/002 28 film-coated tablets EU/1/13/820/003 30 film-coated tablets EU/1/13/820/004 42 film-coated tablets EU/1/13/820/005 50 film-coated tablets EU/1/13/820/006 56 film-coated tablets EU/1/13/820/007 60 film-coated tablets EU/1/13/820/008 70 film-coated tablets EU/1/13/820/009 84 film-coated tablets EU/1/13/820/010 90 film-coated tablets EU/1/13/820/011 98 film-coated tablets EU/1/13/820/012 100 film-coated tablets EU/1/13/820/013 112 film-coated tablets
EU/1/13/820/001: 14 filmom obloženih tableta EU/1/13/820/002: 28 filmom obloženih tableta EU/1/13/820/003: 30 filmom obloženih tableta EU/1/13/820/004: 42 filmom obložene tablete EU/1/13/820/005: 50 filmom obloženih tableta EU/1/13/820/006: 56 filmom obloženih tableta EU/1/13/820/007: 60 filmom obloženih tableta EU/1/13/820/008: 70 filmom obloženih tableta EU/1/13/820/009: 84 filmom obložene tablete EU/1/13/820/010: 90 filmom obloženih tableta EU/1/13/820/011: 98 filmom obloženih tableta EU/1/13/820/012: 100 filmom obloženih tableta EU/1/13/820/013: 112 filmom obloženih tableta
Balance disorders
Često poremećaji ravnoteže
Do not give this medicine to children or adolescents under 18 years of age.
Nemojte davati ovaj lijek djeci ili adolescentima mlađim od 18 godina.
For external use only.
Samo za vanjsku uporabu.
• Ringing in the ears
• zvonjenje u ušima
• a high temperature
• visoka temperatura
The expiry date refers to the last day of that month.
Rok valjanosti se odnosi na zadnji dan navedenog mjeseca.
These effects may be life-threatening.
Takvi učinci mogu biti opasni po život.
Partners completed the PEP questionnaire at month three.
Partneri su popunjavali PEP upitnik u trećem mjesecu.
This is more likely when certain medicines have been taken at the same time.
To je vjerojatnije kad se istovremeno koriste još neki lijekovi.
If this happens, the skin becomes bluish-grey due to a lack of oxygen.
Dogodi li se to, koža postane plavičasto-siva uslijed pomanjkanja kisika.
What Fortacin is and what it is used for
Što je Fortacin i za što se koristi
After first use: 12 weeks
Nakon prvog otvaranja: 12 tjedana
Check the material that your contraceptive or your partner's contraceptive is made of.
Provjerite od kojeg su materijala izrađena kontracepcijska sredstva vas ili partnerice.
If you do apply too much, wipe it off.
Nanesete li previše, obrišite.
Store below 25°C.
Čuvati ispod 25 °C.
Patients should be advised to use alternative methods of contraception.
Bolesnicima treba savjetovati korištenje drugih metoda kontracepcije.
The metal container is pressurised.
Metalni spremnik je pod pritiskom.
• Inability to develop or maintain an erection
• nemogućnost postizanja ili održavanja erekcije
Note, this dose did result in tumours.
Napomena, ta doza je rezultirala tumorima.
• other local anaesthetics
• druge lokalne anestetike
Date of first authorisation: 15 November 2013 Date of latest renewal: 17 September 2018
Datum posljednje obnove odobrenja: 17. rujna 2018.
Pharmaserve (North West) Ltd 9 Arkwright Road Astmoor Industrial Estate Runcorn WA7 1NU United Kingdom
Pharmaserve (North West) Ltd 9 Arkwright Road Astmoor Industrial Estate Runcorn WA7 1NU Ujedinjeno Kraljevstvo
These belong to a group of medicines called local anaesthetics.
Oni pripadaju skupini lijekova pod nazivom lokalni anestetici.
If you use more Fortacin than you should
Ako primijenite više lijeka Fortacin nego što ste trebali
Contents of the pack and other information What Fortacin contains
Sadržaj pakiranja i druge informacije Što Fortacin sadrži
This hypoaesthesia may mask normal pain sensations and, therefore, increase the dangers of localised injury.
Takva hipoestezija može prikrivati normalne osjete boli i posljedično povećati opasnost od lokalnih ozljeda.
Other medicines and Fortacin
Drugi lijekovi i Fortacin
There is limited data on the efficacy and safety of Fortacin in patients 65 years and over.
Podaci o djelotvornosti i sigurnosti lijeka Fortacin u pacijenata u dobi od 65 godina i više su ograničeni.
Also contains: norflurane
Također sadržava: norfluran
However, there may be some exposure in female partners of men treated with Fortacin.
Međutim, može doći do određene izloženosti kod partnerica muškaraca kod kojih je primijenjen Fortacin.
Genotoxicity and carcinogenicity
Genotoksičnost i karcinogenost
Ask your doctor or pharmacist for advice before taking any medicine.
Upitajte svog liječnika ili ljekarnika za savjet prije uzimanja bilo kojeg lijeka.
• local irritation of the throat (if inhaled)
• lokalna iritacija grla (ako se udahne)
This is particularly important if you are taking the following medicines which may interact with Fortacin:
To je osobito važno ako uzimate sljedeće lijekove koji mogu reagirati s lijekom
There are however no systemic exposure data available for comparison with clinical exposure.
Međutim, nema podataka o sistemskom izlaganju za usporedbu s kliničkim izlaganjem.
As this will reduce the ability to feel pain in these areas, extra care should be taken not to injure them until the numbness has worn off.
Kako će to smanjiti osjet bola u tim područjima, potrebna je dodatna briga kako ih ne biste ozlijedili dok utrnulost ne prođe.
Elderly Dosage adjustments are not required in the elderly.
Nije potrebno prilagoditi dozu u starijih osoba.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Pažljivo pročitajte cijelu uputu prije nego počnete primjenjivati ovaj lijek jer sadržava
It should not be punctured, broken or burnt, even when apparently empty.
Ne smije se bušiti, oštetiti ili spaljivati čak i kada izgleda da je prazan.
The medicinal product has a rapid onset of action and is effective within 5 minutes of application.
Lijek ima brzi nastup djelovanja i učinkovit je unutar 5 minuta od nanošenja.
- The other ingredient is norflurane
- Drugi sastojak je norfluran
• failure to ejaculate during sexual intercourse
• neuspješna ejakulacija za vrijeme spolnog odnosa
The systemic clearance is 18 - 64 mL/min/kg.
Sistemski klirens je 18 - 64 mL/min/kg.
During sexual intercourse, a small amount of this medicine may be transferred e.g. to the vagina or the anus.
Za vrijeme snošaja mala količina lijeka može se prenijeti na vaginu, odnosno anus.
However this study did not reproduce the circumstances of clinical use, as the concentration of Fortacin in direct contact with the sperm would be many fold lower.
Međutim, ta studija nije reproducirala okolnosti kliničke primjene, budući da bi tada koncentracija lijeka Fortacin u izravnom kontaktu sa spermom bila višestruko niža.
• Tingling of the skin around the mouth and numbness of the tongue
• trnci na koži oko usta i utrnulost jezika
The potential for reduction of sperm motility following the clinical use of the medicinal product can not be excluded; therefore it is not possible to state whether Fortacin would prevent pregnancy.
Potencijal za smanjenje pokretljivosti spermija nakon kliničke primjene lijeka ne može se isključiti; stoga nije moguće ustvrditi bi li Fortacin spriječio trudnoću.
Breast-feeding This medicine may be used while your partner is breast-feeding.
Dojenje Ovaj lijek može se koristiti dok vaša partnerica doji.
In serious cases of overdose, symptoms may include fits, low blood pressure, slowed breathing, stopped breathing and altered heart beat.
U ozbiljnim slučajevima predoziranja simptomi mogu obuhvaćati i napadaje, nizak krvni tlak, usporeno disanje, zaustavljeno disanje i promijenjen ritam otkucaja srca.
You must throw away the container 12 weeks after you first use it.
Spremnik morate baciti 12 mjeseci nakon prvog korištenja.
First pass metabolism is rapid and extensive and bioavailability is about 35% after oral doses.
Metabolizam prvog prolaza je brz i opsežan, a bioraspoloživost nakon oralnih doza iznosi oko 35 %.
Care should be taken not to allow Fortacin to come in contact with the eye, as it may cause eye irritation.
Potrebno je paziti da Fortacin ne dođe u doticaj s očima budući da može izazvati nadraženost oka.
What Fortacin is and what it is used for What you need to know before you use Fortacin How to use Fortacin
Što je Fortacin i za što se koristi Što morate znati prije nego počnete primjenjivati Fortacin Kako primjenjivati Fortacin
Frequency of the adverse reactions is defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
(≥ 1/1000 do < 1/100), rijetko (≥ 1/10 000 do < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
Do not puncture, break or burn it even when apparently empty.
Nemojte ga bušiti, oštetiti ili spaljivati čak i kada mislite da je prazan.
A maximum of 3 doses can be used within 24 hours with at least 4 hours between doses.
Najviše 3 doze smiju se primijeniti unutar 24 sata uz najmanje 4 sata razmaka između dvije doze.
If you use Fortacin with condoms, you may be more likely to be unable to develop or maintain an erection.
Koristite li Fortacin s kondomom, veća je vjerojatnost da nećete postići ili zadržati erekciju.
Adjusted mean change scores (Fortacin vs. placebo) at Month 3 were 8.2 vs. 2.2 for the ejaculatory control score, 7.2 vs. 1.9 for the sexual satisfaction score, and 3.7 vs. 1.1 for the distress score.
Prilagođene srednje vrijednosti promjene rezultata (Fortacin naspram placebo) u 3. mjesecu bile su 8,2 naspram 2,2 kod bodovanja kontrole ejakulacije, 7,2 naspram 1,9 za bodovanje spolnog zadovoljstva i 3,7 naspram 1,1 za bodovanje tjeskobe.
Should other symptoms of systemic toxicity occur, the signs are anticipated to be similar in nature to those following the administration of local anaesthetics by other routes.
Pojave li se drugi simptomi sistemske toksičnosti, očekuje se da bi njezini znakovi mogli biti po svojoj prirodi slični onima koji nastaju nakon primjene lokalnih anestetika drugim putevima.
Fortacin has no or negligible influence on the ability to drive and use machines.
Fortacin ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Human exposure from Fortacin is 20-30 fold less than the minimum dose that did not result in tumours and 200 fold less than the minimum dose that did result in tumours.
Izloženost lijeku Fortacin u ljudi je 20-30 puta manja od najmanje doze koja nije dovela do razvoja tumora i 200 puta je manja od najmanje doze koja je dovela do razvoja tumora.
Local anaesthetic toxicity is manifested by symptoms of nervous system excitation and, in severe cases, central nervous and cardiovascular depression.
Toksičnost lokalnog anestetika očituje se pojavom simptoma ekscitacije živčanog sustava i, u teškim slučajevima, depresije središnjeg živčanog i kardiovaskularnog sustava.
There was also a significant difference over placebo in all domains for the responses from the partners (p < 0.0001).
Značajna razlika u odnosu na placebo javila se u svim domenama i za odgovore od partnera (p < 0,0001).
This medicinal product may reduce the possibility of pregnancy, but should not be used as a contraceptive.
Ovaj lijek može umanjiti mogućnost trudnoće, ali se ne smije koristiti kao kontraceptiv.
Human exposure is 1000 fold less than than the minimum dose studied.
Izloženost u ljudi je 1000 puta manja od najmanje ispitane doze.
Fortacin is a combination of two medicines: lidocaine and prilocaine.
Fortacin je kombinacija dvaju lijekova: lidokaina i prilokaina.
66.2% of Fortacin-treated subjects and 18.8% of placebo-treated subjects achieved a mean IELT > 2 minutes.
66,2 % ispitanika liječenih lijekom Fortacin i 18,8% liječenih placebom postiglo je srednju vrijednost IELT > 2 minute.
Patients with severe hepatic impairment
Bolesnici s teškim oštećenjem jetre
Women of childbearing potential / contraception in male and females
Žene u reproduktivnoj dobi /kontracepcija u muškaraca i žena
When you use this medicine, particularly during priming of the container, aim the container away from the face to avoid accidental contact with ears, eyes, nose and mouth.
Kada primjenjujete ovaj lijek, posebno tijekom pripreme spremnika za prvu uporabu, usmjerite spremnik dalje od lica kako biste izbjegli slučajan doticaj lijeka s ušima, očima, nosom i ustima.
This is translated into a delaying of the ejaculatory latency time without adversely affecting the sensation of ejaculation.
To se prenosi na produljenje vremena latencije ejakulacije bez narušavanja osjećaja ejakulacije.
Hypersensitivity of the patient or their partner to the active substances or to any of the excipients listed in section 6.1.
Preosjetljivost pacijenta ili njegove partnerice na djelatnu(e) tvar(i) ili neku od pomoćnih tvari navedenih u dijelu 6.1.
How to store Fortacin
Kako primjenjivati Fortacin
The elimination half-life of prilocaine following intravenous administration is approximately 10 - 150 minutes.
Poluvrijeme eliminacije prilokaina nakon intravenske primjene je oko 10 - 150 minuta.
• irritation of the skin
• iritacija kože